ClinicalTrialsFinder

Biomarker-positive EGFR/HER2- Expressing HNSCC Clinical Trials in Shenzhen, Guangdong

1 recruitingShenzhen, Guangdong, China

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC

Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaBiomarker-positive EGFR/HER2- Expressing HNSCC
Beijing Biotech42 enrolled1 locationNCT07617805